The tear-film active

MaquiBright® Maqui Berry — the active studied in screen workers.

A deep-purple berry from Patagonian Chile, standardized to its delphinidin anthocyanins. MaquiBright® is the one active in this formula whose placebo-controlled trial was run in people like you — adults on screens four or more hours a day — at exactly the 60 mg we use.

MaquiBright® · Anklam Extrakt, Germany · Aristotelia chilensis (maqui), Chile

MaquiBright® · Anklam Extrakt · standardized maqui berry

Standardized to delphinidins — the anthocyanins that make maqui purple.

Maqui carries one of the highest anthocyanin loads of any berry on record. MaquiBright® is standardized to at least 25% delphinidins and 35% total anthocyanins, so 60 mg means the same 15 mg of delphinidins its trial delivered.

60 mgthe exact daily dose used in its placebo-controlled trial
≥ 25%delphinidins — the anthocyanins the extract is standardized to
4+ hrsof daily screen time — the trial’s own population

What it does in the eye

  • Supports the eye's natural tear filmIn its placebo-controlled trial, screen workers taking 60 mg a day produced measurably more tear fluid after four weeks.
  • Helps ease dryness and eye fatigue from screen useA thin tear film is what makes long screen hours feel gritty and tired; maqui’s trial was built around exactly that.
  • A source of berry anthocyaninsMaqui carries one of the highest anthocyanin loads of any berry; MaquiBright® concentrates and measures it.
  • Dosed at its studied 60 mg — matched, not sprinkledThe trial dose, in every serving.

What researchers measured — at our 60 mg dose

MaquiBright® · RDBPC

Four weeks, in screen workers

74 adults (30–60) on screens ≥4 hrs/day · randomized, double-blind, placebo-controlled · MaquiBright® 60 mg · 4 weeks · J. Tradit. Complement. Med., 2019

+6.4 mmmore tear fluid (Schirmer test) vs placebo in study participants
60 mgthe dose in the trial — matched to the milligram
4 wkhow long participants were followed

Yamashita et al., J Tradit Complement Med 2019;9(3):172–178. A study of the MaquiBright® ingredient at 60 mg, describing what changed in study participants — not a study of this finished product.

An earlier open-label pilot (Hitoe 2014) compared 30 mg and 60 mg over 60 days; 60 mg is the dose both studies point to.

MaquiBright® is a standardized maqui berry (Aristotelia chilensis) extract. These structure/function statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Cited research is of the maqui ingredient at the branded dose, not this finished formula. Photography shows raw maqui berries, not the capsule.